Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT.

Slides:



Advertisements
Similar presentations
An Essential Component of Health Systems Strengthening Presented on: May 23, 2011 Akiko Maeda Health, Nutrition & Population Network The World Bank.
Advertisements

Cardiac Resynchronization Heart Failure Study Cardiac Resynchronization Heart Failure Study Presented at American College of Cardiology Scientific Sessions.
VALUE BASED CARE: The Role of INTERMACS INTERMACS 8 TH Annual Meeting James B, Young, M.D. Study Chair – INTERMACS May 5 th, 2014.
Major Medical Decisions in Advanced Heart Failure G. Michael Felker, MD, MHS, FACC, FAHA Chief, Heart Failure Section Duke University School of Medicine.
Monica Colvin-Adams, MD Assistant Professor of Medicine Advanced Heart Failure and Transplantation University of Minnesota Compassionate Allowances Outreach.
Donor Utilization: Making Use of a Precious Resource in Cardiac Transplant Jason W. Smith, MD Assistant Professor of Surgery The University of Washington.
Equipoise Does Not Exist for REVIVE IT Andrew Boyle, MD Heart and Vascular Center Director, Florida Chairman of Cardiology Medical Director of Heart Failure,
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Lung Transplantation: What? Who? When? Marshall I. Hertz, MD University of Minnesota Medical School and Fairview-University Medical Center Medical Director,
Quality Cancer Data The Vital Role of Cancer Registrars in the Fight against Cancer Saves Lives.
Clinical Effectiveness of Implantable Cardioverter-Defibrillators Among Medicare Beneficiaries With Heart Failure Adrian F. Hernandez, MD, MHS; Gregg.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
An International Case Study of Lung Transplantation
Treatment of Heart Failure: Beyond Medical Therapy
ASBMT RETREAT INSURANCE FOR CLINICAL TRIALS Keith Sullivan October 3, 2011.
Predicting Patients at Risk for Poor Global Outcomes after DT- MCS Therapy Suzanne V. Arnold, MD, MHA Saint Luke’s Mid America Heart Institute/UMKC May.
BWGHF Liège Heart transplantation 2008.
Predicting Major Outcomes after MCSD Implant 1 Risk Factors for Death, Transplant, and Recovery James Kirklin, MD David Naftel, PhD.
Interagency Registry for Mechanically Assisted Circulatory Support Marissa A. Miller, DVM, MPH National Heart, Lung, & Blood Institute.
Catalyzing Patient Quality of Life Preferences into Medical Care Choices Helen D. Blank, PhD April 2010.
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device and Medical Management in Ambulatory Heart Failure Patients Assessment.
MCS in Special Populations: The Use of Mechanical Support in Adults with Congenital Heart Disease 9 th Annual Meeting May 15, 2015 Christina VanderPluym,MD.
 Total Artificial Heart (TAH) By:Jessica Blandin.
Survival following VAD complications: implications for transplant priority. Todd Dardas, MD, MS May 16, 2015.
Registry Data Collection in Pediatric VADs: Challenges and Opportunities INTERMACS Eighth Annual Meeting May 5, 2014 David Rosenthal, MD Stanford Children’s.
M. JESSUP Tenth International Symposium HEART FAILURE & Co. CARDIOLOGY SCIENCE UPDATE FEMALE DOCTORS SPEAKING ON FEMALE DISEASES Milano aprile 2010.
Disclosures The presenter has no financial involvement with the product or competing products being discussed. The presenter received travel and lodging.
Risk Factors for Adverse Outcome after HeartMate II Jennifer Cowger, MD, MS St. Vincent Heart Center of Indiana Advanced Heart Failure, Transplant, & Mechanical.
When and How to Replace an LVAD
Pediatric Mechanical Circulatory Support (MCS) Ivan Wilmot, MD Heart Failure, Transplant, MCS Assistant Professor The Heart Institute Cincinnati Children’s.
Quality of life in patients with implantable cardioverter defibrillators Author: Camelia Tănăsuc Coordinator: Professor Doctor Dan Dobreanu Coauthors:
Advanced Therapies Lee R. Goldberg, MD, MPH Medical Director, Heart Failure and Cardiac Transplant Program University of Pennsylvania.
Mechanical Circulatory Support in Special Populations Renzo Y. Loyaga-Rendon MD.,PhD.. Assistant Professor Advanced Heart Failure Section University of.
Natural History of Heart Failure
Show Me the Money- Delivering Ethical and Reimbursable Services within Healthcare Payer Sources Amber Heape, MCD, CCC-SLP, CDP Clinical Specialist- PruittHealth.
Eric J Robinson, M.D. Cardiologist April 25, 2015
Graft Dysfunction after Heart Transplantation
Identifying patients for advanced heart failure therapy by screening patients with cardiac resynchronization therapy or implantable cardioverter-defibrillator:
James K. Kirklin, MD, Francis D. Pagani, MD, PhD, Robert L
INTERMACS 10th Annual Meeting March , 2016 Quality of Life
Assist Devices for the Treatment of Cardiogenic Shock
Intermacs and the Scientific Registry of Transplant Recipients (SRTR)
Insights from the NCDR® STS/ACC TVT Registry.
Αντιμετώπιση καρδιακής ανεπάρκειας προχωρημένου και τελικού σταδίου
Fifth INTERMACS annual report: Risk factor analysis from more than 6,000 mechanical circulatory support patients  James K. Kirklin, MD, David C. Naftel,
Liver Transplantation: 50 years
Exploring Early Combination Therapy in PAH
O’Connor Efficacy and Safety of Exercise Training as a Treatment Modality in Patients With Chronic Heart Failure: Results of A Randomized Controlled.
MULTIMORBIDITY: THE MOST COMMON CHRONIC CONDITION
HEART-LUNG TRANSPLANTATION
Heart Failure and Hospital Readmissions
Preventing SCD With a WCD: Reviewing the Results of the VEST Trial
Patient Presentation Patient’s Changing Condition Multiple Considerations To Balance.
Canadian Cardiovascular Society Guidelines on the Use of Cardiac Resynchronization Therapy: Evidence and Patient Selection  Derek V. Exner, MD, MPH, David.
Heart Failure Management
INOVATE-HF Trial design: Patients with heart failure (HF) were randomized to device implant for vagus nerve stimulation (n = 436) versus optimal medical.
Cancer Care Delivery System Transformation
NCM Significance Care Transformation Collaborative of R.I.
HEART-LUNG TRANSPLANTATION
HEART-LUNG TRANSPLANTATION
Long-term mechanical circulatory support (destination therapy): On track to compete with heart transplantation?  James K. Kirklin, MD, David C. Naftel,
Anaerobic threshold responder analysis
HEART-LUNG TRANSPLANTATION
Impact of Marital Status on LVAD Mortality: A Single Center Experience Linda Njoroge MD, Mohamed Khayata MD, Kevin Charnas, Paul Bate, Madison Edge, James.
Coverage and Reimbursement to Genetic Testing
HEART-LUNG TRANSPLANTATION
Heart: Year in Review OSOTC 2018 Transplant Symposium September 7, 2018 Brent C. Lampert, DO, FACC Medical Director, Heart Transplantation and Mechanical.
Linking Intermacs to the World:
Alignment of Comparative Effectiveness through MedaMACS
Presentation transcript:

Josef Stehlik, MD, MPH Associate Professor of Medicine Medical Director, Heart Transplant Program University of Utah School of Medicine Director, ISHLT Transplant Registry No financial relationships to disclose. Are DT / BTT designations still relevant?

The answer may depend on who is asking 1. Payer (health insurance) 2. Provider (advanced heart failure team) 3. Patient

1. Payer perspective VAD indication important for eligibility determination and for budgeting

Payer view (Increasing number of) private insurers - declare indication as BTT vs DT - BTT patients must be listed for transplant before VAD implant (Some) state Medicaid programs - no BTT durable MCS VHA - federal insurer - ‘… heart failure treatment utilizing a VAD or total artificial heart …’

2. Provider perspective (us)

Wever-Pinzon O, Stehlik J. Circulation 2013 Jan 29;127(4) Waiting list mortality

Transplant rate Colvin-Adams M. AJT 2014 UNOS Status Transplanted in status Median waiting time 1A 1B 2 64% 31% 5% 78 days 224 days 618 days Stehlik J, Stevenson LW, Mehra MR. JHLT Oct 2014

Is this a scientific / clinical care proposition or rather expression of desperation? Are DT / BTT designations still relevant?

Proposed revision of US heart allocation Meyer DM, AJT 2014

3. Patient perspective 22-year old patient

Expected survival – 22 year old male 99.4% 99.0% National Vital Statistics Reports. 58 (21), 2010

Clinical scenario 22-year-old Non-ischemic CM NYHA IV / Stage D, now inotrope dependent

Expected survival - medical therapy Clinical trials in NYHA III/IV HF Survival in patients on inotropic support Seattle HF Model

Expected survival

Expected survival – heart transplant

Expected survival – DT VAD Data courtesy of Kirklin JK, Naftel DC

Expected survival - BTT VAD Data courtesy of Kirklin JK, Naftel DC

Expected survival - BTT VAD Data courtesy of Kirklin JK, Naftel DC

Are DT / BTT designations still relevant? Payer - relevant for budgeting (eligibility determination, reimbursement) Provider - prefer the flexibility of adjusting strategy based on circumstances Patient - does not care about our terminology - wants to know the options and likely outcomes to make informed decisions